Rizatriptan: a new 5-HT1B/1D receptor agonist for the treatment of migraine

Bibliography

• STAFFA JA, LIPTON RB, STEWART WF: The epidemiology of migraine headache. Rev. Contemp. Pharmacol. (1994) 5:241–252.
   Google Scholar
• STEWART WF, SHECHTER A, RASMUSSEN BK: Migraine prevalence. A review of population-based studies. Neu-rology (1994) 44 (Suppl. 4) :S17–S23.
   Google Scholar
• STEWART WF, SCHECHTER A, LIPTON: Migraine hetero-geneity. Disability, pain intensity and attack frequency and duration. Neurology (1994) 44(Suppl. :S24–539.
   Google Scholar
• SILBERSTEIN SD: Migraine symptoms: results of a sur- vey of self-reported migraineurs. Headache (1995) 35:387–396.
   PubMed Web of Science ®Google Scholar
• DAHLOF C: Current concepts of migraine and its treat-ment. Neurologia (1999) 14:67–77.
   PubMedGoogle Scholar
• LIPTON RB, STEWART WF: Migraine in the United States: a review of epidemiology and health care use. Neurol-ogy (1993) 43 (Suppl. 3):6–10.
   Google Scholar
• TFELT-HANSEN P, WELCH KMA: General principles of pharmacological treatment. In: The Headaches Olesen J, Tfelt-Hansen P, Welch KMA, (Eds.), Raven Press, New York, USA (1993)299–303.
   Google Scholar
• TFELT-HANSEN P, JOHNSON ES: Nonsteroidal anti-inflammatory drugs in the treatment of the acute mi-graine attack. In: The Headaches Olesen J, Tfelt-Hansen P, Welch KMA, (Eds.), Raven Press, New York, USA (1993):305–311.
   Google Scholar
• TFELT-HANSEN P, JOHNSON ES: Antiemetic and proki-netic drugs. In: The Headaches Olesen J, Tfelt-Hansen P, Welch KMA, (Eds.), Raven Press, New York, USA (1993):343–347.
   Google Scholar
• TFELT-HANSEN P, LIPTON RB: Dihydroergotamine. In: The Headaches Olesen J, Tfelt-Hansen P, Welch KMA, (Eds.), Raven Press, New York, USA (1993):323–327.
   Google Scholar
• TFELT-HANSEN P, JOHNSON ES: Ergotamine. In: The Headaches Olesen J, Tfelt-Hansen P, Welch KMA, (Eds.), Raven Press, New York, USA (1993):313–322.
   Google Scholar
• SILBERSTEIN SD, YOUNG WB: Safety and efficacy of er-gotamine tartrate and dihydroergotamine in the treat-ment of migraine and status migrainous. Neurology (1995) 45:577–584.
   PubMed Web of Science ®Google Scholar
• SAPER JR: Ergotamine dependency - a review. Headache (1987) 27:435–438.
   PubMed Web of Science ®Google Scholar
• FERRARI MD: Migraine. Lancet (1998) 351:1043–1051.
   PubMedGoogle Scholar
• PLOSKER GL, MCTAVISH D: Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs (1994) 47:622–651.
   Google Scholar
• GLAXO WELLCOME, INC.: Imitrex (sumatriptan) tab-lets. Physicians Desk Reference. Medical Economics Company, Montvale NJ, USA (1999):1141–1145.
   Google Scholar
• VISSER WH, JASPERS NWMH, DE VRIED RHM, FERRARI MD: Sumatriptan in clinical practice: a two year review of 453 migraine patients. Neurology (1996) 47:46–51.
   PubMed Web of Science ®Google Scholar
• FERRARI MD, JAMES MH, BATES D et al.: Oral sumatrip-tan: effect of a second dose, and incidence and treat-ment of headache recurrences. Cephalalgia (1994) 14:330–338.
   PubMed Web of Science ®Google Scholar
• HILLIS WS, MACINTYRE PD: Sumatriptan and chest pain. Lancet (1993) 341:1564–1565.
   PubMed Web of Science ®Google Scholar
• PILGRIM AJ, STEWART-LONG, P, FOWLER PA: Intensive ECG surveillance in patients receiving sumatriptan af-ter previous chest symptoms. Cephalalgia (1993) 13\(Suppl. 13):167.
   Google Scholar
• VISSER WH, JASPERS NMWH, DE VRIED RHM, FERRARIMD: Chest symptoms after sumatriptan: a two year clinical practice review in 735 consecutive migraine patients. Cephalalgia (1996) 16:554–559.
   PubMed Web of Science ®Google Scholar
• SOLOMON GD, CADY RK, KLAPPER JA, EARL NL, SAPER JR, RAMADAN NM: Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of mi-graine. Neurology (1997) 49:1219–1225.
   Google Scholar
• RAPOPORT AM, RAMADAN NM, ADELMAN JU: Optimiz-ing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine: a multicenter, double-blind, placebo-controlled dose range-finding study. Neurology (1997) 49:1210–1218.
   PubMed Web of Science ®Google Scholar
• KLASSEN A, ELKIND A, ASGHARNEJAD M, WEBSTER C, LAURENZA A: Naratriptan is effective and well tolerated in the acute treatment of migraine: results of a double-blind, placebo-controlled, parallel-group study. Head-ache (1997) 37:640–645.
   PubMed Web of Science ®Google Scholar
• MATHEW NT, ASGHARNEJAD M, PEYKAMIAN M, LAU-RENZA A: Naratriptan is effective and well-tolerated in the acute treatment of migraine: results of a double-blind, placebo-controlled, crossover study. Neurology (1997) 49:1485–1490.
   PubMed Web of Science ®Google Scholar
• MERCK & CO., INC: Maxalt (rizatriptan) tablets. Physi-cians Desk Reference. Medical Economics Company, Montvale NJ, USA (1999):1822–1827.
   Google Scholar
• GOADSBY P: Serotonin 5-HT1ai1D receptor agonists in migraine: comparative pharmacology and its thera-peutic implications. CNS Drugs (1998) 10:271–286.
   Web of Science ®Google Scholar
• WILLIAMSON DJ, SHEPHEARD SL, HILL RG, HARGREAVES RJ: The novel anti-migraine agent rizatriptan inhibits neurogenic vasodilation and extravasation. Eur. J. Pharmacol. (1997) 328:61–64.
   PubMed Web of Science ®Google Scholar
• CUMBERBATCH MJ, HILL RG, HARGREAVES RJ: Rizatrip-tan has central antinociceptive effects against durally evoked responses. Eur. J. Pharmacol. (1997) 328:37–40.
   PubMed Web of Science ®Google Scholar
• MACINTYRE PD, BHARGAVA MD, HOGG KJ, GEMMILL JD, HILLIS WS: Effect of subcutaneous sumatriptan, a selec-tive 5-HT1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation (1993) 87:401–405.
   PubMed Web of Science ®Google Scholar
• NOVECK RJ, BIALY GP, BRADSTREET TE, GAGLIANO KD,GOLDBERG MR: Effects of rizatriptan on blood pres-sure in hypertensive patients. Clin. Pharmacol. Thera-peut. (1998) 63:186.
   Google Scholar
• SEIDELIN KN, TFELT-HANSEN P, MENDEL CN, STE-PANAVAGE M: Peripheral hemodynamic study of MK-462, ergotamine and their combination. Cephalalgia (1995) 15 (Suppl. 14):207.
   Google Scholar
• TFELT-HANSEN P, SPERLING B, WINTER PD: Transientadditional effect of sumatriptan on ergotamine - induced constriction of peripheral arteries in man. Clin. Pharmacol. Therapeut. (1992) 51:149.
   Web of Science ®Google Scholar
• LONGMORE J, BOULANGER CM, DESTA B, HILL RG, SCHOFIELD WN, TAYLOR AA: 5-HT1u receptor agonists and human coronary artery reactivity in vitro: cross-over comparisons of 5-HT and sumatriptan with rizatriptan and L-741,519. Br. J. Clin. Pharmacol (1996) 42:431–441.
   PubMed Web of Science ®Google Scholar
• MAASENVANDENBRINK A, REEKERS M, BAX WA, FER-RARI MD, SAXENA PR: Coronary side-effect potential of current and prospective antimigraine drugs. Circula-tion (1998) 98:25–30.
   PubMed Web of Science ®Google Scholar
• LONGMORE J, RAZZAQUE Z, SHAW D eta].: Comparison of the meningeal versus coronary artery selectivity of the 5-ffr1si1D receptor agonists rizatriptan and suma-triptan using human isolated blood vessels. Br. J. Clin. Pharmacol (1998) 46:577–582.
   Google Scholar
• DAHLOF CGH, MATHEW N: Cardiovascular safety of 5-HT1Bi1D agonists - is there a cause for concern? Cephalalgia (1998) 18:539–545.
   PubMed Web of Science ®Google Scholar
• SPERLING B, TFELT-HANSEN P, LINES C: Lack of effect of MK-462 on cerebral blood flow in man. Cephalalgia (1995) 15 (Suppl. 14):206.
   Google Scholar
• SCOTT AK, GRIMES S, NG K, CRITCHLEY M, BECKEN-RIDGE AM, THOMSON C, PILGRIM AJ: Sumatriptan and cerebral perfusion in healthy volunteers. Br. J. Clin. Pharmacol (1992) 33:401–404.
   PubMed Web of Science ®Google Scholar
• ANDERSEN AR, TFELT-HANSEN P, LASSEN NA: The effect of ergotamine and dihydroergotamine on cerebral blood flow in man. Stroke (1987) 18:120–123.
   PubMed Web of Science ®Google Scholar
• FRIBERG L, OLESEN J, IVERSEN HK, SPERLING B: Mi-graine pain associated with middle cerebral artery dilatation: reversal by sumatriptan. Lancet (1991) 338:13–17.
   PubMed Web of Science ®Google Scholar
• SCIBERRAS DG, POLVINO WJ, GERTZ BJ et al.: Initial hu-man experience with MK-462 (rizatriptan): a novel 5-HT1p agonist. Br. J. Clin. Pharmacol (1997) 43:49–54.
   PubMed Web of Science ®Google Scholar
• LEE Y, CONROY JA, DE SMET M et al: Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. Br. J. Clin. Pharmacol (1999). In press.
   Google Scholar
• VISSER WH, TERWINDT GM, REINES SA, JIANG K, LINES CR, FERRARI M: Rizatriptan vs sumatriptan in the acute treatment of migraine. Arch. Neurol (1996) 53:1132–1137.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN A, KAUFER D, SHEMER J, HENDLER I, SOREQ H, TUR-KASPA I: Pyridostigmine brain penetration un-der stress enhances neuronal excitability and induces early immediate transcriptional response. Nature Med. (1996) 2:1382–1385.
   PubMed Web of Science ®Google Scholar
• ROLAN P: Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90). Cephalalgia (1997) 17 (Suppl. 18):21–27.
   Google Scholar
• HYLAND R, JONES BC, MCCLEVERTY P, MITCHELL RJ, MORGAN P: In vitro metabolism of eletriptan in human liver. Cephalalgia (1998)18:404.
   Google Scholar
• GLAXO WELLCOME, INC.: Amerge (naratriptan) tablets. Physicians Desk Reference. Medical Economics Company, Montvale NJ, (1999):1086–1090.
   Google Scholar
• GOLDBERG MR, LEE Y, ERMLICH S et al: Single and multiple-dose pharmacokinetics and tolerability of ri-zatriptan, a novel 5-HT1si1D agonist for migraine. Headache (1997) 37:310.
   Google Scholar
• SCOTT AK: Sumatriptan clinical pharmacokinetics. Pharmaco. (1994) 27:337–344.
   Google Scholar
• PECK RW, SEABER EJ, DIXON R et al.: The interaction be-tween propranolol and the novel antimigraine agent zolmitriptan (311C90). Br. J. Clin. Pharmacol (1997) 44:595–599.
   PubMed Web of Science ®Google Scholar
• GOLDBERG MR, LOWRY RC, MUSSON DG et al: Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine. Br. J. Clin. Pharma-col. (1999) 39:1–8.
   Google Scholar
• VAN HAARST AD, VAN GERVEN JMA, COHEN AF, DE SMET M, STERRETT A, GOLDBERG MR: The effects of mo-clobemide on the pharmacokinetics of the 5-HT1Bim agonist rizatriptan in healthy volunteers. Br. J. Clin. Pharmacol (1999). In press.
   Google Scholar
• GIJSMAN H, KRAMER MS, SARGENT J et al.: Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalal-gia (1997) 17:647–651.
   PubMed Web of Science ®Google Scholar
• TEALL J, TUCHMAN M, CUTLER N, GROSS M et al.: Riza-triptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpa-tient study. Headache (1998) 38:281–287.
   Google Scholar
• TFELT-HANSEN P, TEALL J, RODRIGUEZ F et al.: Oral riza-triptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Headache (1998) 38:748–755.
   PubMed Web of Science ®Google Scholar
• LINES C, VISSER WH, VANDORMAEL K, REINES SA: Riza-triptan 5 mg versus sumatriptan 50 mg in the acute treatment of migraine. Headache (1997) 37:319–320.
   Google Scholar
• GOLDSTEIN J, RYAN R, JIANG K et al: Crossover com-parison of rizatriptan 5 mg and 10 mg vs. sumatriptan 25 mg and 50 mg in migraine. Headache (1998) 38:737–747.
   Google Scholar
• KRAMER MS, MATZURA-WOLFE D, POLIS A et al.: A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Neurology (1998) 51:773–781.
   PubMed Web of Science ®Google Scholar
• BLOCK GA, GOLDSTEIN J, POLIS A,REINES SA, SMITH ME:Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Headache (1998) 38:764–771.
   PubMed Web of Science ®Google Scholar
• PFAFFENRATH V, CUNIN G, SJONELL G, PRENDERGAST S: Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache (1998) 38:184–190.
   PubMed Web of Science ®Google Scholar
• DAHLOF C: The consistency of response to oral suma-triptan in the acute treatment of migraine. Poster pre-sented at the 2nd International Conference of the European Headache Federation, Belgium, (1994).
   Google Scholar
• ANTHONY M, RASMUSSEN BK: Migraine without aura. In: The Headaches Olesen J, Tfelt-Hansen P, Welch KMA (Eds.), Raven, New York, USA (1993):255–261.
   Google Scholar
• CULL RE, WELLS NEJ, MIOCEVICH ML: The economic cost of migraine. Br. J. Med. Econ. (1992) 2:103–115.
   Google Scholar
• DASBACH EJ, GERTH WC, PIGEON J, SANTANELLO N, KRAMER M: Measuring the effect of acute migraine and its treatment on paid work and productivity loss in a randomized clinical trial of rizatriptan versus pla-cebo. Headache (1997) 37:304–305.
   Google Scholar
• LLEWELYN JG, FINDLEY LI GROSS MLP: Migraine symp-toms: Which cause the most distress? In: Headache Treatment: Trial Methodology and New Drugs. Olesen J, Tfelt-Hansen P, (Eds.), Lippincott-Raven, Philadelphia, USA (1997):153–156.
   Google Scholar
• DATA ON FILE: A multicenter, double-blind, placebo-controlled study of the cardiovascular safety and toler-ability of MK-0462 in otherwise healthy migraineurs. MRL Clinical Study Report, Protocol 020.
   Google Scholar
• ZENECA PHARMACEUTICALS: Zomig (zolmitriptan) tab-lets. Physicians Desk Reference. Medical Economics Com-pany, Montvale NJ, (1999):3454–3457.
   Google Scholar
• AHRENS SP, VISSER WH, JIANG K, REINES SA: Rizatriptan RPD for the acute treatment of migraine.Poster presented at the 12th Migraine Trust International Sympo-sium, London, UK, (1998).
   Google Scholar
• HEADACHE CLASSIFICATION COMMITTEE OF THE IHS: Classification and diagnostic criteria for headache dis-orders, cranial neuralgias and facial pain. Cephalalgia (1988) 8 (Suppl. 7):1–96.
   Google Scholar
• VISSER WH, JIANG K: Effect of rizatriptan versus suma-triptan on migraine-associated symptoms. Poster pre-sented at the 50th Meeting of the American Academy of Neurology, Minneapolis, USA, (1998). Carl Dahloflt & Christopher Lines2 tAuthor for correspondence
   Google Scholar